Cardioprotection on Chemotherapy-Induced Cardiotoxicity
NCT ID: NCT06853951
Last Updated: 2025-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
30 participants
INTERVENTIONAL
2023-07-18
2025-07-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation and Management of Cardio Toxicity in Oncologic Patients
NCT02818517
Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection
NCT06060132
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
NCT05724121
Detection of Chemotherapy Induced Cardiotoxicity
NCT00636844
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
NCT00292526
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Arm 2 Patients will receive β-blockers oral tablets during Induction Phase by either a caregiver or caring nurse.
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ACEIs
0.3 mg/kg/dose every 8 hours orally by either a caregiver or caring nurse.
ACE Inhibitors
0.3 mg/kg/dose every 8 hours orally by either a caregiver or caring nurse.
β-blockers
0.05 mg/kg/dose every 12 hours orally by either a caregiver or caring nurse
β -Blockers
0.05 mg/kg/dose every 12 hours orally by either a caregiver or caring nurse.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACE Inhibitors
0.3 mg/kg/dose every 8 hours orally by either a caregiver or caring nurse.
β -Blockers
0.05 mg/kg/dose every 12 hours orally by either a caregiver or caring nurse.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to take oral medication.
* Age 2-18 years at the time of diagnosis.
Exclusion Criteria
1 Year
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
keristin nazir
Teaching Assistant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manal Hamed El-Hamamsy, Prof
Role: PRINCIPAL_INVESTIGATOR
Ain Shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Pharmacy, Ain Shams University
Cairo, , Egypt
Faculty of Pharmacy, Ain Shams University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
315
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.